Atlas Trials

Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients

Clinical trial NCT06015126 · UNKNOWN

Trial details

NCT number
NCT06015126
Sponsor
Yan Xue
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
Breast Cancer
Start date
2022-10-05
Primary completion
2025-01-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.